Torrent Pharma Peer Comparison

NSE: TORNTPHARM | BSE: 500420

₹4,890.00

₹-42.00 (-0.85%)

As on 26-Aug-2026IST

Market cap

₹1,85,924 Cr

Revenue (TTM)

₹15,723 Cr

P/E Ratio

85.2

P/B Ratio

20.7

Div. Yield

0.8 %

Edit

	Torrent Pharma	Sun Pharmaceutical	Cipla	Zydus Lifesciences	Lupin
Market cap (₹ Cr)	1,85,924	4,56,114	1,13,778	1,14,508	1,00,196
Revenue (₹ Cr)	15,723	59,911	28,324	28,592	29,967
Net Profit (₹ Cr)	2,156.00	12,172.70	3,364.84	4,492.20	5,551.01
Net Margin (%)	13.77	19.41	11.54	14.92	18.23
RoE (%)	26.88	15.65	10.63	18.78	28.32
Price to Earnings	85.25	37.71	33.76	25.37	18.12
Price-To-Book	20.71	5.27	3.24	4.25	4.21

Income Statement (₹ Cr)

	Torrent Pharma	Sun Pharmaceutical	Cipla	Zydus Lifesciences	Lupin
Operating Revenue	15,723.00	59,910.52	28,324.40	28,591.70	29,966.58
Total Income	15,654.00	62,725.79	29,158.75	30,111.40	30,442.31
Total Expenditure	10,532.00	42,647.50	22,985.32	21,334.70	20,428.27
EBITDA	5,191.00	17,263.02	5,339.08	7,257.00	9,538.31
Depreciation	1,511.00	2,976.02	1,304.52	1,724.60	1,529.37
EBIT	3,680.00	14,287.00	4,034.56	5,532.40	8,008.94
Interest	634.00	363.78	57.37	510.20	452.37
Other Income	-69.00	2,815.27	834.35	1,519.70	475.73
Exceptional Items	-110.00	-693.57	-275.91	-534.80	-557.91
Profit before Tax	2,867.00	16,044.92	4,535.63	6,007.10	7,474.39
Provision for Tax	711.00	3,872.22	1,170.79	1,514.90	1,923.38
Profit after Tax	2,156.00	12,172.70	3,364.84	4,492.20	5,551.01

	Torrent Pharma	Sun Pharmaceutical	Cipla	Zydus Lifesciences	Lupin
Shareholder's Funds	8,389.00	83,570.09	34,431.95	27,111.40	22,448.27
Minority Interest	25.00	-21.43	14.98	-79.70	-22.18
Non-Current Liabilities	18,384.00	2,283.44	962.15	7,112.50	3,200.22
Current Liabilities	8,343.00	22,622.04	7,013.59	15,711.90	12,651.24
Total Liabilities	43,613.69	1,08,407.20	42,342.71	50,672.60	38,146.06

	Torrent Pharma	Sun Pharmaceutical	Cipla	Zydus Lifesciences	Lupin
Non-Current Assets	33,955.00	43,711.29	15,471.21	31,677.20	11,888.82
Current Assets	9,392.00	63,860.29	24,145.86	19,906.10	24,027.38
Total Assets	43,613.69	1,08,407.20	42,342.71	50,672.60	38,146.06
Total Debt*	14,798.24	4,081.61	257.97	11,769.50	5,910.20
Net Current Assets	1,049.00	41,238.25	17,132.27	4,194.20	11,376.14
Contingent Liabilities	379.25	1,587.05	987.37	989.90	1,094.02

	Torrent Pharma	Sun Pharmaceutical	Cipla	Zydus Lifesciences	Lupin
Cash From Operating Activities	3,022.71	12,419.18	3,940.02	2,116.60	7,334.50
Cash Flow from Investing Activities	-12,712.41	-11,344.05	-2,326.13	-8,296.10	-3,864.59
Cash from Financing Activities	10,150.60	-2,512.55	-1,233.65	5,806.90	-845.87
Net Cash Inflow / Outflow	460.90	-1,437.42	380.24	-372.60	2,624.04

	Torrent Pharma	Sun Pharmaceutical	Cipla	Zydus Lifesciences	Lupin
ROCE (%)	19.27	19.11	16.00	21.39	28.86
ROE (%)	26.88	15.65	10.63	18.78	28.32
ROA (%)	7.27	12.12	8.42	10.03	16.43
EBIT Margin (%)	23.41	23.85	14.24	19.35	26.73
Net Margin (%)	13.77	19.41	11.54	14.92	18.23
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Torrent Pharma	Sun Pharmaceutical	Cipla	Zydus Lifesciences	Lupin
Revenue Growth (%)	32.85	11.41	1.85	21.11	28.19
EBIT Growth (%)	20.66	8.10	-33.61	-8.99	77.03
Net Profit Growth (%)	7.69	16.92	-37.77	-3.14	49.13
EPS Growth (%)	12.04	10.18	-33.63	4.31	60.86
Book Value Growth (%)	10.51	15.72	10.59	13.19	30.75

	Torrent Pharma	Sun Pharmaceutical	Cipla	Zydus Lifesciences	Lupin
Price / Earnings	73.09	36.11	31.78	23.43	16.81
Price / Book Value	20.71	5.27	3.24	4.25	4.21
Dividend Yield (%)	0.78	0.84	0.92	0.09	0.82
EV/EBITDA	38.28	24.77	19.68	16.41	10.16
Market Cap (₹ Cr)	1,42,851.87	4,21,639.92	98,797.18	87,643.18	1,05,737.27

	Torrent Pharma	Sun Pharmaceutical	Cipla	Zydus Lifesciences	Lupin
Debt to Equity	1.39	0.00	0.00	0.12	0.07
Short term debt to equity ratio	0.35	0.05	0.00	0.16	0.18
Current Ratio	1.13	2.82	3.44	1.27	1.90
Quick Ratio	0.75	2.31	2.50	0.91	1.42
Interest Coverage	5.52	45.11	80.06	12.77	17.52

	Torrent Pharma	Sun Pharmaceutical	Cipla	Zydus Lifesciences	Lupin
Debtors to sales (%)	19.28	25.89	19.84	18.94	22.04
Asset Turnover	0.53	0.60	0.71	0.64	0.89
Receivable days	45.41	89.14	52.05	33.55	51.23
Inventory Days	52.67	67.85	57.25	33.80	48.93
Payable days	244.06	213.72	115.96	149.82	205.75
Cash Conversion Cycle	-145.98	-56.72	-6.65	-82.46	-105.59

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.